Treatment of Iron Deficiency with or without Anaemia with Intravenous Ferric Carboxymaltose in Gynaecological Practices – A Non-Interventional Study

Therapie des Eisenmangels mit oder ohne Anämie mit intravenöser Eisencarboxymaltose in der gynäkologischen Praxis – eine nicht interventionelle Studie

Authors
R. Herfs1, L. Fleitmann2, I. Kocsis3

Affiliations
1 Gynaecological Practice, Grünwald
2 Dortmund Gynaecology and Obstetrics, Dortmund
3 Gynaecology and Obstetrics Practice, Bonn

Key words
- intravenous iron substitution
- ferric carboxymaltose
- iron deficiency anaemia
- hypermenorrhoea
- menorrhagia
- post partum

Schlüsselwörter
- intravenöse Eisensubstitution
- Eisencarboxymaltose
- Eisenmangelanämie
- Hypermenorrhö
- Menorrhagie
- post partum

Abstract
In this multi-centre, prospective, non-interventional study, the effectiveness and tolerance of ferric carboxymaltose (ferinject®; FCM) was tested through use in standard gynaecological practice. In total, data from 273 patients was evaluated. 193 of these patients displayed iron deficiency anaemia (IDA), and 68 had iron deficiency without anaemia (ID). The reasons for the ID/IDA were hypermenorrhoea (HyM) (n = 170), post-partum condition (PP) (n = 53) or another indication (n = 53). The average age of the patients was 40 years old, with 8% of them being vegetarians. Half of the patients had already been treated for anaemia, primarily with oral iron products (94%). The primary, serious accompanying symptoms of anaemia were fatigue (72%), lack of concentration (42%), pale mucous membranes (42%), headache (26%) and sleep disorders (21%). Only one patient did not show serious symptoms at the start of the study. The most frequent indications for parenteral therapy were the need for rapid iron substitution to reduce symptoms (> 70%), followed by the lower effectiveness or intolerance of oral products (42%) each as well as patients not completing the course of treatment with oral products (12%). Patient information was collected at both the beginning and the end of the observation period, which lasted 15 weeks. FCM was most frequently administered via infusion (92%; average infusion duration 21 minutes). Seven percent of patients received bolus injections. The average total iron dosage per patient was 788.7 mg (median 550 mg; range: 50–3000 mg); the median individual dosage was 500 mg (range: 50–1000 mg). The total dosage was, in most cases, administered through a single application (range: 1–10). Symptoms, blood values (Hb), iron stores (serum-ferritin [S-ferritin]) and transport iron (transferrin saturation [TSAT]) normalised to a large extent. In all subgroups, 92%...
of women displayed a marked improvement in all of their symptoms. The average increase in Hb-value in the group as a whole was statistically significant, increasing from 10.5 to 13.0 g/dl. In the group with anaemia, the value increased from 9.9 to 13.3 g/dl, with 80% of women reaching normal Hb-values. The average S-ferritin value increased by a statistically significant >70 µg/L from 17.2 to 88.8 µg/l and the value for the TSAT increased from 16.3% to 22.8%. Seven patients reported experiencing side effects. None of the results were severe. Overall, as part of this non-interventional study for everyday routine in a gynaecological practice, a rapid improvement in symptoms accompanied by the rectification of iron deficiency and anaemia was shown with low occurrences of mild undesirable events, and therefore the data obtained from controlled clinical studies on the effectiveness and tolerance of intravenous ferric carboxymaltose could be confirmed.

**Introduction**

There have been numerous international investigations into the treatment of iron deficiency (ID)/anaemia or iron deficiency anaemia (IDA) with regard to severity, diagnosis or aetiology [1–6]. Women in particular are affected by iron deficiency with or without anaemia: up to 22% of women in industrialised nations are sufferers, while the figure is one in two women in developing countries [1,2,7]. There are three main conditions seen commonly in gynaecological practices that can lead to IDA: lack of iron intake [8,9], hypermenorrhoea (HyM) [10] or pregnancy/post-partum condition (PP) [11–15]. Distressing symptoms of anaemia occur as a result of oxygen deficiency and the body’s efforts to compensate for it: tiredness, irritability, skin and mucous membrane paleness, dizziness or apnoea. The following symptoms may additionally occur as a result of isolated ID: headache, cognitive disturbances, depression, in particular post-partum depression.

The rationale for treatment of IDA is ensuring systemic oxygen supply on the one hand and improving the prognosis of severe underlying illnesses on the other. The normalisation of anaemia also goes hand in hand with a considerable improvement in quality of life [16–19]. If the symptoms of iron deficiency are greatly pronounced and a change in diet, particularly in the case of a vegetarian diet, is not promising, medicinal iron substitution remains the treatment of choice for gynaecological indications in particular. The primary treatment method is through oral medication, which is replaced by parenteral preparations in the event of intolerance and/or ineffectiveness [20].

Indications for intravenous iron substitutions include unfluenceable gastrointestinal intolerances to oral preparations [2, 21–27]. Alongside absolute ID through significant losses such as bleeding or through inadequate uptake, indications for parenteral iron treatment also include functional iron deficiency, tumour anaemia, anaemia from chronic illness and erythropoetin (EPO) [2,22,26].

The comparison between different iron preparations administered orally or applied parenterally showed a significant need for easier to handle and better tolerated therapeutic alternatives. The iron ions released to varying degrees through the oral administration of iron preparations can lead to a broad spectrum of gastrointestinal irritations. With oral treatment, iron stores are only increased very slowly, meaning that oral treatment has to be administered consistently over many months. The parenteral preparations used were iron-carbohydrate complexes, whereby there are significant differences with regard to stability or the incidence of anaphylactic reactions [28]. It is desirable for the iron complex to be highly stable in order to prevent the occurrence of toxic iron ions in the serum. Stable preparations can therefore be administered more quickly and in higher dosages [29].

Ferric carboxymaltose (ferinject® [FCM], Vifor Pharma) is a relatively newly developed, dextran-free iron complex with high complex stability. This enables the intravenous application of up to 1000 mg of iron in a single dosage as a 15 minute short-term infusion [30]. Effectiveness, safety and tolerance have been documented by numerous controlled and randomised studies on over 6500 patients with different underlying illnesses, including patients with renal insufficiency [4,31], chronic inflammatory bowel diseases [32], cardiac insufficiency [33,34] as well as in women with hypermenorrhoea or post-partum anaemia [4,13,22,35–38]. The results of a meta-analysis of 14 phase III studies, in which a total of 2348 patients received iron carboxymaltose and 1978 patients received iron orally or intravenously or a placebo, confirm its positive effectiveness and safety profile [5]. According to the guidelines from the German Society for Haematology and Oncology (DGHO), ferric carboxymaltose offers the most effective option to substitute iron intravenously [2,13].

The study presented here aims to clarify to what extent the results of controlled prospective studies, including multicentred application under practice conditions, reflect how treatment with ferric carboxymaltose is carried out as part of the everyday routine at gynaecological practices with regard to dosage and application, and which advantages and disadvantages participants experience.

**Patients and Methods**

The analysis presented here is based on a prospective, non-interventional study on the treatment of iron deficiency with intravenously administered ferric carboxymaltose in gynaecological patients. Inclusion and exclusion criteria were the only binding stipulations in the study’s observation plan. Diagnosis, treatment decisions and prescriptions, treatment in accordance with the information specified in the authorisation, as well as follow-up in accordance with the customary methods in the respective medi-
cal practice and their documentation were the sole responsibility of the attending doctor [39]. The study was presented to the relevant authorities and associations, indicating all the necessary information, sent to the ethical commission of the Bavarian Medical Council for assessment and listed in the VfA (German Association of Research-Based Pharmaceutical Companies) register [40]. The study began in February 2011. The duration of the study was 15 months.

**Study aims and inclusion criteria**

The primary aims of the study were to test the effectiveness and tolerance of FCM under the conditions of a medical gynaecological practice in ID patients with or without anaemia caused by hypermenorrhoea, post-partum condition or other causes of iron deficiency. The primary endpoints of the data analyses were changes in Hb content, S-ferritin level, serum TSAT as well as the type and severity of accompanying clinical symptoms over the course of treatment. Secondary endpoints were the type and number of undesired events and changes in safety-related laboratory parameters, the evaluation of treatment regimes used in the practice as well as the type of anti-anaemic pretreatment and concomitant treatment. Inclusion criteria were female sex, age ≥ 18 years, diagnosis of iron deficiency, FCM naivety, pre-existing treatment indication for FCM due to hypermenorrhoea (subgroup “HyM”), post-partum anaemia (subgroup “PP”) or other non-obvious causes (subgroup “Other”) as well as the patient having signed a written informed consent form. Exclusion criteria were pregnancy, chronic kidney disease, Crohn’s disease, ulcerative colitis, heart failure or an active malignant process.

**Data collection, documentation and data analysis**

The two documentation dates were the day of acceptance into the study (baseline, BSL) and the end of the observation period (end of study, EOS). The envisaged duration of observation for each individual patient was 4 to 12 weeks, regardless of the number of consultations. The data collected by the practice as a matter of course through a standardised registration form which collects demographic basic information was also used for the study documentation, as was illness-related data from the patient history or ongoing observation. The effects of FCM in all patients as well as subgroups were analysed, stratified according to the reason for the iron deficiency (“HyM”; “PP”) as well as according to the existence of iron deficiency with anaemia (IDA) or without anaemia (ID).

Before analysis, the data was checked for quality and plausibility as well as normal distribution. As in a non-interventional study there is no follow-up to complete the data sets beyond the data that the practice normally collects, this data is not always complete. This generally only enables evaluation through descriptive, statistical methods. The percentage frequency, the median with minimum and maximum values (range, spread), the quartiles, if applicable, and the average value are used to describe the frequency distribution. A two-way t-test per student was only used to describe the differences between BSL and EOS for the Hb and S-ferritin levels.

**Results**

67 gynaecological practices in Germany participated in the study. Of the 303 patients recruited, 273 were treated with FCM and formed the safety group, with 271 being assessable and representing the effectiveness group. Of these, 170 patients were assigned to the “HyM” subgroup, of which 117 (69%) had iron deficiency anaemia (“IDA”). 53 patients were treated post partum, with only eight (15%) of them having iron deficiency without concomitant anaemia (“ID”). The cause of ID could not be directly determined in 53 patients, 34 (64%) of whom had anaemia (“Other”). Post-partum condition as well as hypermenorrhoea were given as the reasons for ID/IDA in five patients. Ten women were not able to be assigned to the IDA/ID groups due to a lack of relevant basic data (e.g. serum ferritin and TSAT).

**Patient demographics, anti-anaemia pre-treatment; symptoms, anaemia and iron status at the start of the study**

The average age of all patients was 40 years. Only women with post-partum condition (“PP”) were younger, as expected, with an average age of 30.8 years. The most noticeable deviations from the average values were shown in the patients of the “Other” subgroup. They had a significantly lower body weight and were more likely to be vegetarian. The demographic information is detailed in Table 1.

At the start of the study, anaemia was moderate on average (Hb 10.5 g/dL; S-ferritin 17.2 µg/L and TSAT 16.3%) (cf. Tables 4 and 5). The clinical symptoms of fatigue, lack of concentration and pale mucous membranes were greatly pronounced in 72% and 42% of patients respectively. 61% of patients had been treated for anaemia in the six-month period prior to acceptance in the study. The oral administration of anti-anaemia medication was the most common form of administration (93%). Iron injections were only administered to six women. Erythropoietin was not administered before or during the study. The most common reason for the introduction of intravenous FCM treatment was the necessity for rapid iron substitution (73%) to get symptoms under control, followed by insufficient effectiveness (37%) or lack of tolerance (35%) to previous oral iron treatment.

**Duration of observation and iron treatment**

The average duration of observation for all patients was 15.1 weeks. Deviations from the average value in the subgroups were low (from −0.6 in the case of “PP” to +1.1 in the case of “ID”). The average duration of treatment, defined as the period between the first and last administration of FCM, was 18.6 days. For the majority of patients (n = 250; 92.3%), treatment was administered according to plan in the observation period. The only additional treatment for anaemia, accompanying treatment with FCM, was oral iron substitution. The percentages of patients affected in the subgroups were as follows: “PP”: n = 12 (22.6%); “HyM”: n = 31 (18.2%); “Other”: n = 7 (13.2%); “ID”: n = 10 (14.7%) and “IDA”: n = 37 (19.2%) of patients. The average total iron dosage (TID) administered per patient was 788.7 mg of iron, with a median value of 550 mg, over a broad range of 50–3000 mg. Table 2 shows the dosages in the subgroups. Differentiating TID by the HB levels at the start of the study resulted in a trend towards the administration of higher dosages in the case of a lower initial Hb value. The individual iron dosage (SID) was between 50 and 1000 mg. The most common (50%) SID applied was between 500 and 1000 mg, with the median SID being 500 mg. Most patients (91.9%) received FCM in the form of an intravenous drip (infusion), with 7% receiving a bolus injection and 1.1% receiving both. The average number of applications was 2.1. The maximum value was 10 infusions. The duration of the intravenous drips was between 4 and
84

Demographic data for all subgroups.

Table 1

<table>
<thead>
<tr>
<th>Patient subgroups</th>
<th>Demographics</th>
<th>HyM* (n = 170)</th>
<th>PP* (n = 53)</th>
<th>Other (n = 53)</th>
<th>IDΔ (n = 68)</th>
<th>IDAΔ (n = 193)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average age (years)</td>
<td>39</td>
<td>40.5</td>
<td>30.8</td>
<td>42.1</td>
<td>39.5</td>
<td>38.9</td>
</tr>
<tr>
<td>Average weight (kg)</td>
<td>67.8</td>
<td>68.8</td>
<td>69.9</td>
<td>63.2</td>
<td>68.5</td>
<td>67.7</td>
</tr>
<tr>
<td>Vegetarians (%)</td>
<td>8.2</td>
<td>7.1</td>
<td>9.4</td>
<td>9.4</td>
<td>8.8</td>
<td>8.3</td>
</tr>
<tr>
<td>BMI (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;26 (kg/m²)</td>
<td>76.3</td>
<td>75.6</td>
<td>69.2</td>
<td>86.3</td>
<td>74.6</td>
<td>77</td>
</tr>
<tr>
<td>26–31 (kg/m²)</td>
<td>14.5</td>
<td>13.4</td>
<td>19.2</td>
<td>11.8</td>
<td>13.4</td>
<td>14.4</td>
</tr>
<tr>
<td>&gt;31 (kg/m²)</td>
<td>9.2</td>
<td>9.0</td>
<td>11.5</td>
<td>2</td>
<td>11.9</td>
<td>8.6</td>
</tr>
</tbody>
</table>

Risk factors (%)

- Diabetes | 1.8 | 0.6 | 5.7 | 1.9 | 0 | 2.6 |
- Hypertension | 6.3 | 8.2 | 3.8 | 3.8 | 7.4 | 6.2 |
- Smoking | 9.6 | 9.5 | 11.3 | 7.5 | 5.9 | 10.4 |
- Obesity | 13 | 15.4 | 13.2 | 5.7 | 13.2 | 14.4 |

Subgroups: Hypermenorrhoea (HyM), post partum (PP), other reasons (Other) as well as without anaemia (ID) or with anaemia (IDA)

Δ Ten patients were not able to be assigned to the anaemic/non-anaemic groups due to a lack of relevant basic data.

70 minutes, with the median being 20 minutes. Lower or higher doses of iron were infused for the same length of time. The infusion volumes were between 10 and 250 ml of physiological NaCl and the median was 153.3 ml. There was no trend towards the use of higher dilution volumes for higher individual doses. The details for the number of FCM infusions are shown in Table 3.

Symptoms, anaemia and iron status over the course of the study

The frequency of severe pronounced clinical symptoms at the start of the study: fatigue in 72.3% of patients, lack of concentration (42.1%), pale mucous membranes (41.7%), headache (26.2%), alopecia (23.2%), sleep disorders (21.4%), depression (18.1%), dyspnoea (14.4%) and muscular symptoms/RLS (10.7%). The frequency of individual symptoms does not differ significantly or systematically in the subgroups (Fig. 1). An improvement in all symptoms was observed in a high percentage of patients (n = 243; 91.7%) and in all subgroups between BSL and EOS. Severe pronounced symptoms in particular such as fatigue, lack of concentration and pale mucous membranes decreased significantly in all subgroups. The number of completely symptom-free women increased from 1 (0.4%) at BSL to 22 (8.1%) at EOS.

The distribution of the Hb level at BSL corresponded to a left-skewed normal distribution: 65% of patients with Hb <8 g/dl, 30% with 8 to <10 g/dl, 41.7% with 10 to <12 g/dl and 21.9% with ≥12 g/dl. The Hb value for the effectiveness group increased from 10.5 ± 1.79 g/dl at BSL to 13.0 ± 1.56 g/dl at EOS. The average increase was 2.4 ± 2.08 mg/dl, with the difference between BSL and EOS being statistically significant. 79.7% of patients achieved normal Hb values (≥12 g/dl) by EOS. In total, the Hb value increased by at least ≥1 g/dl in 138 patients (71.5%). Of these, 96 (49.7%) displayed an increase by ≥2 g/dl and 65 (33.7%) by ≥3 g/dl. Table 4 shows the results of treatment, including for the subgroups, based on average values.

S-ferritin increased on average by 71.5 ± 123.86 µg/l following intravenous FCM treatment. Table 5 reflects the laboratory values. The increase is statistically significant. The BSL S-ferritin value of 88.9% of recorded patients (n = 162) was below the standard range. By EOS, this had been reduced to 9.9%. There were no differences in values between patients with or without anaemia. The difference in TSAT between BSL and EOS could be determined in 46 patients. The average values increased from 16.3% to 22.8%. Only 2 (4.3%) of patients had normal TSAT values (20–45%) at BSL, compared with 28 out of 46 patients at EOS (60.9%).

Table 2

<table>
<thead>
<tr>
<th>Patient subgroups</th>
<th>Total iron dosage (mg)</th>
<th>HyM* (n = 170)</th>
<th>PP* (n = 53)</th>
<th>Other (n = 53)</th>
<th>IDΔ (n = 68)</th>
<th>IDAΔ (n = 193)</th>
</tr>
</thead>
<tbody>
<tr>
<td>M</td>
<td>788.7</td>
<td>842.9</td>
<td>693.4</td>
<td>713.2</td>
<td>646.3</td>
<td>861.7</td>
</tr>
<tr>
<td>Range</td>
<td>50–3000</td>
<td>50–2500</td>
<td>50–1500</td>
<td>50–3000</td>
<td>100–2000</td>
<td>100–3000</td>
</tr>
<tr>
<td>Median</td>
<td>550</td>
<td>650</td>
<td>600</td>
<td>500</td>
<td>500</td>
<td>500</td>
</tr>
<tr>
<td>q1; q3</td>
<td>500; 1000</td>
<td>500; 1000</td>
<td>500; 1000</td>
<td>500; 850</td>
<td>500</td>
<td>500</td>
</tr>
<tr>
<td>Individual iron dosage (mg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>478.7</td>
<td>510.8</td>
<td>437.7</td>
<td>418.3</td>
<td>449.1</td>
<td>501.5</td>
</tr>
<tr>
<td>Range</td>
<td>50–1000</td>
<td>50–1000</td>
<td>50–1000</td>
<td>50–1000</td>
<td>100–1000</td>
<td>100–1000</td>
</tr>
<tr>
<td>Median</td>
<td>500</td>
<td>500</td>
<td>500</td>
<td>500</td>
<td>500</td>
<td>500</td>
</tr>
<tr>
<td>q1; q3</td>
<td>250; 500</td>
<td>300; 500</td>
<td>200; 500</td>
<td>212.5; 500</td>
<td>337.5; 500</td>
<td>250; 500</td>
</tr>
</tbody>
</table>

Subgroups: Hypermenorrhoea (HyM), post partum (PP), other reasons (Other) as well as without anaemia (ID) or with anaemia (IDA)

Δ Ten patients were not able to be assigned to the anaemic/non-anaemic groups due to a lack of relevant data.
Tolerance

The safety group consisted of 273 women, with a total of 21 undesirable events (UE) being reported by seven women. Twelve UEs in five patients were designated as being certain or probable in relation to the medication. Four women reported mild hypersensitivity reactions (itching, urticarial rash or exanthema), one woman with pre-existing psoriasis, hashimoto thyreoiditis and house dust allergy reported a severe hypersensitivity reaction (generalised urticarial rash, mild itching and nausea with a drop in blood pressure to 100 mmHg), with all patients recovering fully from the UEs.

Table 3  Average number of intravenous ferric carboxymaltose applications.

<table>
<thead>
<tr>
<th>Patient subgroups</th>
<th>all (n = 271)</th>
<th>HyM* (n = 170)</th>
<th>PP* (n = 53)</th>
<th>Other (n = 53)</th>
<th>ID § (n = 68)</th>
<th>IDA § (n = 193)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of infusions (n)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients</td>
<td>252</td>
<td>161</td>
<td>45</td>
<td>51</td>
<td>5</td>
<td>238</td>
</tr>
<tr>
<td>M</td>
<td>1.9</td>
<td>2.0</td>
<td>1.5</td>
<td>2.0</td>
<td>2.2</td>
<td>1.9</td>
</tr>
<tr>
<td>Range</td>
<td>1–10</td>
<td>1–10</td>
<td>1–3</td>
<td>1–10</td>
<td>1–4</td>
<td>1–10</td>
</tr>
<tr>
<td>Number of injections (n)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients</td>
<td>22</td>
<td>11</td>
<td>10</td>
<td>2</td>
<td>0</td>
<td>21</td>
</tr>
<tr>
<td>M</td>
<td>4.2</td>
<td>4.3</td>
<td>4.3</td>
<td>3.0</td>
<td>Ø</td>
<td>4.3</td>
</tr>
<tr>
<td>Range</td>
<td>1–10</td>
<td>1–7</td>
<td>1–10</td>
<td>1–5</td>
<td>Ø</td>
<td>1–10</td>
</tr>
<tr>
<td>Applications per patient (n)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients</td>
<td>271</td>
<td>170</td>
<td>53</td>
<td>53</td>
<td>5</td>
<td>256</td>
</tr>
<tr>
<td>M</td>
<td>2.1</td>
<td>2.1</td>
<td>2.1</td>
<td>2.1</td>
<td>2.2</td>
<td>2.1</td>
</tr>
<tr>
<td>Range</td>
<td>1–10</td>
<td>1–10</td>
<td>1–10</td>
<td>1–10</td>
<td>1–4</td>
<td>1–10</td>
</tr>
</tbody>
</table>

Subgroups: Hypermenorrhoea (HyM), post partum (PP), other (Other) as well as without anaemia (ID) or with anaemia (IDA)

n = number of patients; M = average value; range: minimum and maximum value

* Post-partum condition as well as hypermenorrhoea were given as the reasons for ID/IDA in five patients.

§ Ten patients were not able to be assigned to the anaemic/non-anaemic groups due to a lack of relevant data.

Fig. 1  Relative frequency of severely pronounced clinical symptoms at the beginning (BLS) and at the end (EOS) of the study in the individual subgroups: Hypermenorrhoea (HyM), post partum (PP), other (Other) as well as without anaemia (ID) or with anaemia (IDA)
Discussion

Proof of effectiveness in medicine is carried out through controlled, clinical studies of varying restrictive designs. They are set up in such a way that differences between groups can become as clear as possible. Unlike with controlled clinical studies, expert information is the only guide for the medication under investigation in non-interventional studies. In general, non-interventional studies contribute to the recording, representation and optimisation of the patient sample, incidences of illnesses and treatments, the type of methods used and the results of treatments, frequently under practice conditions. The inclusion of patients in a non-interventional study, the diagnosis as well as type and extent of therapeutic measures to be employed are at the discretion of the doctor; making decisions in advance or external interventions are not allowed [40, 41].

The multicentred, non-interventional study, carried out in a practice, using ferric carboxymaltose in gynaecological iron deficiency conditions presented here reflected the results found in many controlled gynaecological studies [19, 35, 36, 38] with ferric carboxymaltose. A direct numerical comparison between individual studies is problematic due to the differing study facilities, durations and aims. Nevertheless, some significant results can be compared.

In this non-interventional study, a + 2.5 g/dl increase in Hb values was seen over an observation period of 15 weeks. The corresponding values from controlled studies were around + 3 g/dl [35, 36]. The Hb value normalised, in the study presented, in 80% of patients, in comparison with between 73% and 91% in three controlled and randomised studies [19, 35, 36]. Under practice conditions, the increase of S-ferritin (71.5 µg/l) after 15 weeks was considerably lower than changes usually described in S-ferritin, i.e. of + 210 µg/l [35, 36] after six weeks or of + 122 µg/l

### Table 4
Average Hb values (g/dl), their level, their average change (mΔ-Hb) and the extent of normalisation (> 12 g/dl) between the start of the study (BSL) and the end (EOS).

<table>
<thead>
<tr>
<th>Patient subgroups</th>
<th>all (n = 271)</th>
<th>HyM* (n = 170)</th>
<th>PP* (n = 53)</th>
<th>Other (n = 53)</th>
<th>ID§ (n = 68)</th>
<th>IDA§ (n = 193)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSL Patients (n)</td>
<td>247</td>
<td>154</td>
<td>51</td>
<td>47</td>
<td>54</td>
<td>193</td>
</tr>
<tr>
<td>Hb (g/dl)</td>
<td>10.5</td>
<td>10.5</td>
<td>10.1</td>
<td>11.2</td>
<td>12.9</td>
<td>9.9</td>
</tr>
<tr>
<td>EOS Patients (n)</td>
<td>195</td>
<td>121</td>
<td>44</td>
<td>35</td>
<td>45</td>
<td>148</td>
</tr>
<tr>
<td>Hb (g/dl)</td>
<td>13.0</td>
<td>13.0</td>
<td>12.8</td>
<td>13.1</td>
<td>13.3</td>
<td>12.8</td>
</tr>
<tr>
<td>mΔ-Hb Patients (n)</td>
<td>193</td>
<td>119</td>
<td>44</td>
<td>35</td>
<td>45</td>
<td>148</td>
</tr>
<tr>
<td>ΔHb (g/dl)</td>
<td>+ 2.4</td>
<td>+ 2.5</td>
<td>+ 2.7</td>
<td>+ 1.8</td>
<td>+ 0.5</td>
<td>+ 3.0</td>
</tr>
<tr>
<td>Hb≥ 1 standard</td>
<td>79.7</td>
<td>80</td>
<td>86.5</td>
<td>69.6</td>
<td>n. a.</td>
<td>79.7</td>
</tr>
</tbody>
</table>

Subgroups: Hypermenorrhoea (HyM), post partum (PP), other reasons (Other) as well as without anaemia (ID) or with anaemia (IDA)

n = number; mΔ-Hb = average change in Hb level; Hb≥ 1 standard = increase of Hb within the standard range

* Post-partum condition as well as hypermenorrhoea were given as the reasons for ID/IDA in five patients.

§ Ten patients were not able to be assigned to the anaemic/non-anaemic groups due to a lack of relevant data.

### Table 5
Lab values for serum ferritin (S-ferritin) (µg/l) and transferrin saturation (TSAT) (%) between the beginning of the study (BSL) and the end of the study (EOS).

<table>
<thead>
<tr>
<th>S-ferritin (µg/l)</th>
<th>Patient subgroups</th>
<th>all (n = 271)</th>
<th>HyM* (n = 170)</th>
<th>PP* (n = 53)</th>
<th>Other (n = 53)</th>
<th>ID§ (n = 68)</th>
<th>IDA§ (n = 193)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSL Patient (n)</td>
<td>214</td>
<td>140</td>
<td>41</td>
<td>38</td>
<td>53</td>
<td>157</td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>17.2</td>
<td>11.3</td>
<td>21.5</td>
<td>34.8</td>
<td>15</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>EOS Patient (n)</td>
<td>177</td>
<td>114</td>
<td>38</td>
<td>30</td>
<td>44</td>
<td>130</td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>88.8</td>
<td>82.6</td>
<td>74.4</td>
<td>128.5</td>
<td>89.2</td>
<td>89.1</td>
<td></td>
</tr>
<tr>
<td>ΔBSL/EOS Patient (n)</td>
<td>162</td>
<td>107</td>
<td>35</td>
<td>25</td>
<td>43</td>
<td>116</td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>+ 71.5</td>
<td>+ 73.1</td>
<td>+ 57.6</td>
<td>+ 81</td>
<td>+ 76</td>
<td>+ 70.4</td>
<td></td>
</tr>
<tr>
<td>↑ standard (%)</td>
<td>74.3</td>
<td>74.3</td>
<td>71.4</td>
<td>78.9</td>
<td>78.6</td>
<td>73</td>
<td></td>
</tr>
<tr>
<td>TSAT (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BSL Patient (n)</td>
<td>85</td>
<td>52</td>
<td>18</td>
<td>16</td>
<td>12</td>
<td>72</td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>16.3</td>
<td>12.2</td>
<td>16.1</td>
<td>30.3</td>
<td>10.3</td>
<td>17.6</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>6</td>
<td>5</td>
<td>5.7</td>
<td>16.5</td>
<td>13</td>
<td>5.1</td>
<td></td>
</tr>
<tr>
<td>EOS Patient (n)</td>
<td>77</td>
<td>50</td>
<td>20</td>
<td>11</td>
<td>18</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>22.8</td>
<td>21.8</td>
<td>22</td>
<td>29.5</td>
<td>28.1</td>
<td>21.3</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>21</td>
<td>21</td>
<td>20.4</td>
<td>30</td>
<td>26.5</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>ΔBSL/EOS M</td>
<td>+ 12.8</td>
<td>+ 13.5</td>
<td>+ 8.3</td>
<td>+ 15.7</td>
<td>+ 22</td>
<td>+ 38</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>+ 12.2</td>
<td>+ 10.5</td>
<td>+ 11.2</td>
<td>+ 15.4</td>
<td>+ 26</td>
<td>+ 10.6</td>
<td></td>
</tr>
<tr>
<td>↑ standard (%)</td>
<td>64.3</td>
<td>66.7</td>
<td>50</td>
<td>83.3</td>
<td>71.4</td>
<td>61.8</td>
<td></td>
</tr>
</tbody>
</table>

Subgroups: Hypermenorrhoea (HyM), post partum (PP), other reasons (Other) as well as without anaemia (ID) or with anaemia (IDA)

M = average value; ↑ standard = increase in standard range, ΔBSL/EOS = difference between BSL and EOS

* Post-partum condition as well as hypermenorrhoea were given as the reasons for ID/IDA in five patients.

§ Ten patients were not able to be assigned to the anaemic/non-anaemic groups due to a lack of relevant data.
The specific advantages of ferric carboxymaltose over other parenteral or oral iron preparations as part of the everyday routine at gynaecological practices are considerable. The lower resorption rate and corresponding longer treatment time with limited gastrointestinal tolerance of oral iron medication are thus avoided [36]. This is particularly advantageous when quick iron substitution is needed. Iron dextran was widespread in intravenous iron therapy, as it can be infused in high doses up to 1000 mg, although infusion takes between three and six hours. Also of considerable importance when choosing ferric carboxymaltose as intravenous iron treatment is the fact that, with FCM, there is no danger of anaphylaxis caused by dextran antibodies, as has been reported when using high and low-molecular iron dextran [11,43]. In this respect, the development of the dextran-free formulations of iron-gluconate [44] and iron-sucrose [45] has already resulted in progress in terms of manageability and safety, as these preparations are complexes with an iron oxide/hydroxide core and a carbohydrate shell that are very stable, meaning that fewer free, toxic iron ions are released into the blood [7,46,47]. They too, however, have considerable disadvantages in comparison with ferric carboxymaltose. The problem is not only that lower iron quantities are infused, which takes considerably longer, but also that both are less stable than ferric carboxymaltose [48].

Conclusion for Clinical Practice

In daily work at a gynaecological practice, a latent or manifest iron deficiency is often not diagnosed, as this is primarily not the reason for the medical consultation. This patient group is mainly made up of adolescent and young women in school or further education, whose iron deficiency is not a result of other underlying illnesses. These groups of young women are very aware of nutrition, but cannot guarantee a sufficient iron intake in a low-iron diet. Iron deficiency anaemia is inevitable in the case of chronic blood loss, e.g. through hypermenorrhoea. The consequences for this target group are striking: tiredness, learning deficit, lack of concentration, cognitive deficits, and all this in a time of life in which these abilities are of particular importance in order to ensure learning aims and education success. Intravenous treatment with ferric carboxymaltose is easy to implement in gynaecological practices, is effective and is well-tolerated. The possibility of normalising iron levels even in the case of pronounced anaemia with only one or two applications over a short time keeps the strain on the patients and the expense for the practice low.

Acknowledgements

The authors would like to thank all of the doctors, patients and medical personnel who took part and who made a great contribution to the study.

Conflict of Interest

This paper was supported by Vifor Pharma Deutschland GmbH. Olof Harlin, Vifor Pharma Deutschland GmbH, contributed to the composition of the manuscript.
References

1 WHO; CDC. Assessing the iron status of populations 2004. Online: who.int/publications/2004/9241593156_eng.pdf; last access: 20.03.2012


5 Moore AR, Gaskell H, Rose P et al. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published data. BMC Blood Disorders 2011; 11: 4


7 Dietzfelbinger H, Hubmann M. Eisenmangelanämie. DBI 2012; 2: 6–16


11 Quinibi WT. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforsch 2010; 60 (Ga): 399–412


23 Lipp HP. Peroral und intravenös anwendbare Eisenpräparate. Krankenhauspharmazie 2011; 32: 450–459


28 Geisser P. Pharmakologie und Sicherheitsprofil von Ferric Carboxymaltose (Ferinject®); Struktur/Reaktivitäts-Verhältnisse von Eisenpräparaten. Port J Nephrol Hypert 2009; 23: 11–16


30 Vifor Pharma. Fachinformation – ferinject®, Oktober 2013


42 Raspe F, Breymann C. Diagnosis and therapy of anaemia in pregnancy and puerperium – a survey of obstetric clinics in Switzerland. Geburtsh Frauenheilk 2011; 71: 595–600


44 Sanofi Aventis. Ferrlecit summary of product characteristics. September 2013

45 Vifor Pharma Ltd. Venofer summary of product characteristics. September 2013

